Rhesus diploid rabies vaccine (adsorbed) , a new rabies vaccine. II. Results of clinical studies simulating prophylactic therapy for rabies exposure

Berlin, B.S.; Mitchell, J.R.; Burgoyne, G.H.; Brown, W.E.; Goswick, C.

JAMA 249(19): 2663-2665


ISSN/ISBN: 0098-7484
PMID: 6341639
Document Number: 217486
Rhesus diploid-cell-strain vaccine (RDRV) (adsorbed) is a new rabies vaccine intended for use in man. Volunteers (60) were given 5 doses of RDRV at 0, 3, 7, 14 and 28 days to simulate prophylactic treatment of persons exposed to a rabid animal. Volunteers (35) were given commercial high-titer rabies immune globulin, 20 IU/kg, before the 1st dose of RDRV, and 25 were given RDRV without prior rabies immune globulin. Antibody responses at 14, 28 and 42 days were comparable with those reported with human diploid rabies vaccine. Simulated postexposure prophylactic treatment with RDRV was associated with acceptable levels of local and constitutional symptoms.

Document emailed within 1 workday
Secure & encrypted payments